Chemotherapy News and Research

Latest Chemotherapy News and Research

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for HPV-associated head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of cancer immunotherapies, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated head and neck cancer.

6 Nov 2013

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Sound Pharmaceuticals has successfully completed enrollment of its Phase 2 clinical trial with SPI-1005 at the University of Florida. This study enrolled 80 healthy subjects with normal or slight hearing loss and exposed the volunteer to calibrated music using an iPod and insert earphones.

5 Nov 2013

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

Biothera announced today top-line results from its Phase 2b clinical trial in non-small cell lung cancer (NSCLC) that evaluated its immunotherapeutic drug candidate, Imprime PGG®, with cetuximab (Erbitux®), carboplatin and paclitaxel compared with the monoclonal antibody and chemotherapy combination alone.

5 Nov 2013

The Princess Margaret Cancer Foundation launches innovative Fall advertising campaign

The Princess Margaret Cancer Foundation launches an innovative Fall advertising campaign this month which focuses on the extraordinary team of 63 surgeons, all of whom who are integral reasons why the Princess Margaret Cancer Centre is one of the top 5 cancer research centres in the world.

5 Nov 2013

Experimental drug effective in treating patients with non-small cell lung cancer

An experimental cancer drug that has shown promise in the treatment of melanoma has also shown early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death among men and women worldwide.

4 Nov 2013

$IOF outlines guidelines to help prevent osteoporosis and fractures in cancer patients$

IOF outlines guidelines to help prevent osteoporosis and fractures in cancer patients

Cancer is a health burden of increasing importance which affects close to 13 million people globally. Bone is often affected in these patients, frequently because of bone metastases, or as a result of anti-cancer therapies which can contribute to bone loss and fragility.

4 Nov 2013

Study: Dual-pronged strategy could successfully treat childhood cancer

A dual-pronged strategy using two experimental cancer drugs together could successfully treat a childhood cancer by inhibiting tumour growth and blocking off the escape routes it uses to become resistant to treatment, finds a new study.

3 Nov 2013

DNA methylation signature marks recurrence in early stage lung cancer

An international research team has identified a DNA methylation signature that identifies patients with stage I non-small-cell lung cancer who are at high risk for relapse.

31 Oct 2013

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Two targeted anticancer drugs used together after first-line chemotherapy for advanced stage non-small-cell lung cancer improve progression-free survival, the results of a large, prospective study show.

31 Oct 2013

Early stem cell transplants does not improve overall survival in non-Hodgkin's lymphoma patients

Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine.

31 Oct 2013

UofL researcher enters into license and research collaboration agreement with Novartis

The University of Louisville today announced that researcher Dr. Suzanne Ildstad, representing Regenerex LLC, has entered into a license and research collaboration agreement with Novartis to provide access to stem cell technology that has the potential to help transplant patients avoid taking anti-rejection medicine for life and could serve as a platform for treatment of other diseases.

31 Oct 2013

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of a Phase II study of APD403 in the prevention of chemotherapy-induced nausea & vomiting (CINV).

30 Oct 2013

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced the acquisition of patents for DJ5, a novel non-TZD PPARgamma agonist with potential to retard progressive renal failure in patients with autosomal dominant polycystic kidney disease ("ADPKD').

29 Oct 2013

Researchers identify possible causes of colorectal cancer resistance to bevacizumab drug

A University of Colorado Cancer Center study published in the journal PLOS ONE shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor.

29 Oct 2013

Cytrx announces Q3 2013 financial results, provides clinical update

CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three and nine-month periods ended September 30, 2013, and provided a clinical update.

29 Oct 2013

Eisai supplies diethylcarbamazine citrate 100 mg tablets to WHO

Eisai Co., Ltd. announced today that it has begun the free supply of diethylcarbamazine citrate (DEC) 100 mg tablets produced at its Vizag Plant in India to the World Health Organization in line with its commitment to help WHO in its global effort to eliminate lymphatic filariasis in targeted developing and emerging countries.

29 Oct 2013

Pharmalink's Busulipo receives FDA orphan drug designation

Pharmalink AB, a specialty pharma company focused on orphan and niche products, today announces its product Busulipo, a best-in-class conditioning agent for use in cancer patients prior to hematopoietic stem cell transplantation (HSCT; also known as bone marrow transplantation), has received orphan drug designation from the US Food and Drug Administration.

29 Oct 2013

New unique nanostructure to target drug-delivery treatment of cancer cells

A unique nanostructure developed by a team of international researchers, including those at the University of Cincinnati, promises improved all-in-one detection, diagnoses and drug-delivery treatment of cancer cells.

29 Oct 2013

Current drugs may harbor small-cell lung cancer promise

Scientists have identified several existing non-oncology drug classes that may have potential as a treatment for small-cell lung cancer, especially for patients with chemoresistant and metastatic disease.

28 Oct 2013

Chemotherapy News and Research

Latest Chemotherapy News and Research

FDA grants Orphan Drug Designation to Advaxis' ADXS-HPV for HPV-associated head and neck cancer

Sound Pharmaceuticals completes enrollment for SPI-1005 Phase 2 clinical trial

Biothera announces top-line results from Phase 2b clinical trial in non-small cell lung cancer

The Princess Margaret Cancer Foundation launches innovative Fall advertising campaign

Experimental drug effective in treating patients with non-small cell lung cancer

IOF outlines guidelines to help prevent osteoporosis and fractures in cancer patients

Study: Dual-pronged strategy could successfully treat childhood cancer

DNA methylation signature marks recurrence in early stage lung cancer

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Early stem cell transplants does not improve overall survival in non-Hodgkin's lymphoma patients

UofL researcher enters into license and research collaboration agreement with Novartis

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

Acacia Pharma begins APD403 Phase II study to prevent chemotherapy-induced nausea & vomiting

3Sbio acquires patents for DJ5 to delay hereditary renal disease in ADPKD patients

Researchers identify possible causes of colorectal cancer resistance to bevacizumab drug

Cytrx announces Q3 2013 financial results, provides clinical update

Eisai supplies diethylcarbamazine citrate 100 mg tablets to WHO

Pharmalink's Busulipo receives FDA orphan drug designation

New unique nanostructure to target drug-delivery treatment of cancer cells

Current drugs may harbor small-cell lung cancer promise

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Newsletters you may be interested in